Back to top
more

Anixa Biosciences (ANIX)

(Delayed Data from NSDQ)

$3.10 USD

3.10
53,923

-0.05 (-1.59%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.08 -0.02 (-0.65%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Apellis (APLS) Plunges on Safety Issues With Eye Treatment

by Zacks Equity Research

Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).

Zacks Equity Research

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

Zacks Equity Research

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

by Zacks Equity Research

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.

Zacks Equity Research

Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study

by Zacks Equity Research

Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.

Zacks Equity Research

Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study

by Zacks Equity Research

Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.

Zacks Equity Research

Acadia (ACAD) Expands Existing Licensing Deal With Neuren

by Zacks Equity Research

Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.

Zacks Equity Research

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

by Zacks Equity Research

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

Zacks Equity Research

Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study

by Zacks Equity Research

Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.

Zacks Equity Research

Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%

by Zacks Equity Research

Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.

Zacks Equity Research

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

by Zacks Equity Research

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.

Zacks Equity Research

What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock

by Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Alnylam (ALNY) Reports Positive Results From APOLLO-B Study

by Zacks Equity Research

Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.

Zacks Equity Research

Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%

by Zacks Equity Research

Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.

Zacks Equity Research

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

by Zacks Equity Research

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

Zacks Equity Research

Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag

by Zacks Equity Research

Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.

Zacks Equity Research

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Zacks Equity Research

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

by Zacks Equity Research

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

Zacks Equity Research

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

Zacks Equity Research

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Zacks Equity Research

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

by Zacks Equity Research

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Zacks Equity Research

Here's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price Strength

by Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

by Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Zacks Equity Research

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

by Zacks Equity Research

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.